11/18/2015 - 7:59am

Steven Collis has served as president and CEO of AmerisourceBergen since July 2011 and a director since May 2011.

11/17/2015 - 2:29pm

Mylan has launched its generic of Axert, a treatment for migraines. 

11/17/2015 - 12:58pm

Ajanta is launching its fifth generic product in the U.S. that has received Food and Drug administration approval. 

11/16/2015 - 11:38am

Mylan has launched two generics — one for diabetes and another for HIV — following final Food and Drug Administration approval. 

11/13/2015 - 10:09am

Perrigo’s shareholders did not tender a majority of the company’s shares to Mylan by 8 a.m. EST Friday, effectively ending Mylan’s acquisition attempt. 

11/11/2015 - 2:16pm

The drug is indicated to treat and prevent low levels of potassium (hypokalemia). 

11/11/2015 - 11:13am

A merger frenzy has hit the generics sector this year with a spate of acquisitions and hostile-takeover bids making headlines and reshaping the industry.

11/11/2015 - 11:13am

As 2015 draws to a close, the year is on track to be one in which the value of the branded drugs losing their patent protection approaches an all-time high. The dozens of drugs that will have lost their patent protection this year are estimated to have global sales of $44 billion a year — the highest total since $53 billion worth of medications went off patent in 2012.

11/11/2015 - 11:13am

Rapidly rising prices for many generics, regulations that could restrict patients’ access to these medications, a Food and Drug Administration backlog in getting new drugs approved and market consolidation that is reducing competition are all making some wonder how much longer generics will continue to be affordable.